Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy.
BACKGROUND
Interferon-beta (IFNβ) regulates the expression of a complex set of pro- as well as anti-inflammatory genes. In cohorts of MS patients unstratified for therapeutic response to IFNβ, normal vaccine-specific immune responses have been observed. Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFNβ-therapy are not available.


OBJECTIVE
To assess antigen-specific immune responses in a cohort of MS patients responding clinically and radiologically to IFNβ.


METHODS
In 26 MS patients, clinical and MRI disease activity were assessed before and under treatment with IFNβ. Humoral and cellular immune response to influenza vaccine was prospectively characterized in these individuals, and 33 healthy controls by influenza-specific Enzyme-Linked Immunosorbent Assay (ELISA) and Enzyme Linked Immuno Spot Technique (ELISPOT).


RESULTS
Related to pre-treatment disease activity, IFNβ reduced clinical and radiological MS disease-activity. Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.


CONCLUSIONS
By showing in a cohort of MS-patients responding to IFNβ vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFNβ-therapy.
Immunobiology Laboratory, Department of Biomedicine and Medical Outpatient Department, University Hospital Basel, Basel, Switzerland ; Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Matthias
M
Mehling
Stefanie
S
Fritz
Patricia
P
Hafner
Dominik
D
Eichin
Tomomi
T
Yonekawa
Thomas
T
Klimkait
Raija L P
RL
Lindberg
Ludwig
L
Kappos
Christoph
C
Hess
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000097:blood*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D009975:Orthomyxoviridae / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D014611:Vaccination
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007252:Influenza Vaccines; D016899:Interferon-beta